Abstract:
A hybrid polypeptide is disclosed, comprising a polypeptide for attachment of a prosthetic group to avidin fused to at least one polypeptide of interest, and a method of making the same. The hybrid polypeptide is produced by recombinant DNA techniques, using a DNA expression vector composed of a DNA fragment coding for the polypeptide for attachment to avidin fused to DNA coding for one or more polypeptides of interest. The hybrid polypeptide may also contain linking amino acid sequences for cleavage of the polypeptide of interest from the polypeptide for attachment using an appropriate proteolytic or chemical reagent. The hybrid polypeptide is expressed in appropriate host cells transformed with the DNA expression vector encoding the hybrid polypeptide, and may be recovered from crude cell extracts in high yield and high purity using avidin affinity chromatography. Following avidin affinity purification, the polypeptide for attachment and polypeptide of interest may be cleaved to yield polypeptide of interest in a highly pure and highly active state.
Abstract:
Provided is a caffeoylalphaneoendrophin peptide derivative, and use thereof, as an anti-itching agent and an anti-atopic agent. More specifically, provided is a caffeoyl endorphin peptide derivative, which is applicable in a cosmetic material for anti-inflammatory use, such as for an atopic dermatitis treatment, and the like. The caffeoyl endorphin peptide derivative is safe for skin, has resistance to degradation by peptidases, and the like, and also has an excellent stability with respect to temperature change, and the like.
Abstract:
The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X.
Abstract:
The present invention provides an expression vector comprising genes encoding OmpF of E. coli and a desired protein, E.coli transformed with the expression vector, and a method for extracellular production of desired proteins by employing the same. The recombinant expression vector of the invention comprises an ampicillin-resistance gene, the OmpF promoter and the OmpF gene. In accordance with the invention, a desired protein can be produced extracellularly by a simpler method than conventional methods such that: secretory production of OmpF fusion protein begins simultaneously with growth of the cells through constitutive expression employing an OmpF promoter, and as the concentration of cells increases, the amount of secretory production of the protein also increases continuously. Therefore, desired proteins can be produced in large quantities by a high concentration culture of cells.
Abstract:
The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage including a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) covalently bound to X.
Abstract:
Novel carboxyl terminus analogs of .beta.-endorphin are described. The carboxyl terminus of such analogs is selected from lower alkyl amide, glycine, glycinamide, or polyglycine. These analogs exhibit either greater analgesic activity than the parent .beta.-endorphin and/or increased binding activity in an opiate binding assay.
Abstract:
An untriakontapeptide having significant opiate agonist activity has been isolated from camel pituitary glands. The structure of this peptide has been determined and this peptide was then synthesized utilizing solid phase peptide synthesis. Both natural and synthetic material show identical physical and biological properties.
Abstract:
The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage including a pharmacologically active peptide sequence (X) and a stabilising petide sequence (Z) covalently bound to X.
Abstract:
The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage including a pharmacologically active peptide sequence (X) and a stabilising petide sequence (Z) covalently bound to X.
Abstract:
Described are rapid and highly efficient procedures for the total synthesis of linear, double stranded DNA sequences of up to about 200 base pairs, which sequences may comprise entire structural genes. Illustratively disclosed is the preparation and expression of manufactured genes, including fusion genes, capable of directing synthesis of human .beta.-endorphin and of proteins which differ from human .beta.-endorphin in terms of the identity or relative position of one or more amino acids. Manufactured genes preferably include codons selected from among alternative codons specifying the same amino acid on the basis of preferential expression in a projected host microorganism (e.g., E. coli) to be transformed.